GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena
SUZHOU, China, May 12, 2026 /PRNewswire/ -- As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention. Mean...